SWOG clinical trial number
S2114

A Randomized Phase II trial of consolidation therapy following CD19 CAR T-cell treatment for Relapsed/Refractory Diffuse Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Open
Phase
Accrual
10%
Abbreviated Title
Ph II consolidation therapy following CD19 CAR-T for R/R DLBCL or Gr III FL
Status Notes
Activated: Effective Thursday, February 23, 2023 at 12:00 PM Pacific Time
Activated
02/23/2023
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS

Research committees

Lymphoma

Treatment

Mosunetuzumab Polatuzumab vedotin

Eligibility Criteria Expand/Collapse

*Please review Section 5: Eligibility of the protocol for eligibility criteria.*

Publication Information Expand/Collapse

2023

SWOG 2114: A Randomized Phase II Trial of Consolidation Therapy following CD19 CAR T-cell Treatment for Relapsed/Refractory Large B-cell or Grade IIIB Follicular Lymphoma

B Hess;H Li;N Hossain;V Beylergil;C Sauter;M Hamadani;J Svoboda;A Major;B Kahl;J Leonard;S Smith;M LeBlanc;P Stiff;JW Friedberg Hematology Oncology Vol 41, Issue S2; ICML (June 13 to June 17, 2023, Lugano, Switzerland), publication only

2022

A non-factorial analysis of a factorial Phase II trial design to evaluate single agent and combination consolidation therapies following CD19 CAR T-cell therapy for relapsed/refractory diffuse large B cell lymphoma (R/R DLBCL): SWOG-S2114

H Li;M LeBlanc;B Hess;N Hossain;SM Smith;P Stiff;J Friedberg Society for Clinical Trials (MAY 15-18, 2022 San Diego, CA), poster

Reports & Approvals

Trial Locations